Terms: = Kidney tumors AND PRCC, Q92733, TPRC, RCCP1, MGC4723, MGC17178, ENSG00000143294, 5546
586 results:
1. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract] [Full Text] [Related]
2. Single nucleotide polymorphism (SNP) chromosomal microarray as a diagnostic tool for mucinous tubular and spindle cell carcinoma: A validation study.
Nielson KJ; Rowsey R; Dasari S; Sukov WR; Kipp BR; Raghunathan A; Whaley RD; Ebare K; Stanton ML; Reynolds JP; Sharma V; Thompson RH; Boorjian SA; Leibovich BC; Hernandez LH; Jimenez RE; Cheville JC; Gupta S
Hum Pathol; 2024 Apr; 146():57-65. PubMed ID: 38615998
[TBL] [Abstract] [Full Text] [Related]
3. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract] [Full Text] [Related]
4. Implications of MTHFD2 expression in renal cell carcinoma aggressiveness.
Silva RVN; Berzotti LA; Laia MG; Araújo LS; Silva CA; Ribeiro KB; Brandão M; Michelleti AMR; Machado JR; Lira RCP
PLoS One; 2024; 19(2):e0299353. PubMed ID: 38422037
[TBL] [Abstract] [Full Text] [Related]
5. Biphasic papillary (biphasic squamoid alveolar) renal cell carcinoma: a clinicopathologic and molecular study of 17 renal cell carcinomas including 10 papillary adenomas.
Nova-Camacho LM; Acosta AM; Akgul M; Panizo A; Galea LA; Val-Carreres A; Talavera JA; Guerrero-Setas D; Martin-Arruti M; Ruiz I; García-Martos M; Sangoi AR
Virchows Arch; 2024 Mar; 484(3):441-449. PubMed ID: 38388964
[TBL] [Abstract] [Full Text] [Related]
6. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis.
Prakasam G; Mishra A; Christie A; Miyata J; Carrillo D; Tcheuyap VT; Ye H; Do QN; Wang Y; Reig Torras O; Butti R; Zhong H; Gagan J; Jones KB; Carroll TJ; Modrusan Z; Durinck S; Requena-Komuro MC; Williams NS; Pedrosa I; Wang T; Rakheja D; Kapur P; Brugarolas J
J Clin Invest; 2024 Feb; 134(7):. PubMed ID: 38386415
[TBL] [Abstract] [Full Text] [Related]
7. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract] [Full Text] [Related]
8. Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry.
Saitta C; Afari JA; Walia A; Patil D; Tanaka H; Hakimi K; Wang L; Meagher MF; Liu F; Nguyen MV; Puri D; Cerrato C; Saidian A; Kobayashi M; Fukuda S; Fujii Y; Master V; Derweesh IH
Urol Oncol; 2024 Apr; 42(4):119.e1-119.e16. PubMed ID: 38341362
[TBL] [Abstract] [Full Text] [Related]
9. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy.
Larrinaga G; Valdivia A; Arrieta-Aguirre I; Solano-Iturri JD; Ugalde-Olano A; Loizaga-Iriarte A; Santos-Martín A; Pérez-Fernández A; Angulo JC; López JI
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338778
[TBL] [Abstract] [Full Text] [Related]
10. Clear-cell papillary renal cell tumour: New insights into clinicopathological features and molecular landscape after renaming by 5th WHO classification.
Zhang W; Zhang L; Wen Z; Liang J; Wang Y; Wang Z; Yin Z; Fan L
Pathol Res Pract; 2024 Mar; 255():155167. PubMed ID: 38324963
[TBL] [Abstract] [Full Text] [Related]
11. CT features based preoperative predictors of aggressive pathology for clinical T1 solid renal cell carcinoma and the development of nomogram model.
Wang K; Dong L; Li S; Liu Y; Niu Y; Li G
BMC Cancer; 2024 Jan; 24(1):148. PubMed ID: 38291357
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.
Hong SH; Lee YJ; Jang EB; Hwang HJ; Kim ES; Son DH; Park SY; Moon HS; Yoon YE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203388
[TBL] [Abstract] [Full Text] [Related]
13. Mesenchymal-Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis.
Moraes FCA; Vilbert M; Alves VFC; de Oliveira Almeida G; Priantti JN; Madeira T; Stecca C; Fernandes MR; Dos Santos NPC
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139411
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
Wei S; Krause HB; Geynisman DM; Elliott A; Kutikov A; Uzzo RG; Pei J; Barata P; Carneiro B; Heath E; Ryan C; Farrell A; Nabhan C; Ali-Fehmi R; Naqash AR; Argani P; McKay RR
Mod Pathol; 2024 Feb; 37(2):100404. PubMed ID: 38104891
[TBL] [Abstract] [Full Text] [Related]
15. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
Doğan K; Onder E
Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
[TBL] [Abstract] [Full Text] [Related]
16. Potential role of
Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
[TBL] [Abstract] [Full Text] [Related]
17. Role of Contrast-Enhanced Ultrasound With the Enhancement Pattern and Qualitative Analysis for Differentiating Hypovascular Solid Renal Lesions.
Li J; Huang X; Wang L; Wang X; Li Y; Liu X; Ye N; Yang S; Nie F
Ultrasound Med Biol; 2024 Feb; 50(2):295-303. PubMed ID: 37996360
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
de Vries-Brilland M; Rioux-Leclercq N; Meylan M; Dauvé J; Passot C; Spirina-Menand E; Flippot R; Fromont G; Gravis G; Geoffrois L; Chevreau C; Rolland F; Blanc E; Lefort F; Ravaud A; Gross-Goupil M; Escudier B; Negrier S; Albiges L
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935564
[TBL] [Abstract] [Full Text] [Related]
19. 2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Schmeusser BN; Patil DH; Nicaise EH; Armas-Phan M; Nabavizadeh R; Narayan VM; Joshi SS; Ogan K; Osunkoya AO; Bilen MA; Master VA
Cancer; 2024 Feb; 130(3):453-466. PubMed ID: 37803521
[TBL] [Abstract] [Full Text] [Related]
20. Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors.
Kim B; Lee S; Moon KC
Hum Pathol; 2023 Dec; 142():1-6. PubMed ID: 37797754
[TBL] [Abstract] [Full Text] [Related]
[Next]
